PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,922,971 | -8.8% | 667,596 | +26.0% | 0.00% | – |
Q2 2023 | $7,587,352 | +129.1% | 529,843 | +14.3% | 0.00% | – |
Q1 2023 | $3,311,125 | -67.3% | 463,743 | -48.6% | 0.00% | – |
Q4 2022 | $10,128,272 | +105.2% | 902,698 | +102.6% | 0.00% | – |
Q3 2022 | $4,936,000 | +43.0% | 445,495 | +9.0% | 0.00% | – |
Q2 2022 | $3,451,000 | -30.5% | 408,882 | +12.0% | 0.00% | – |
Q1 2022 | $4,968,000 | -26.1% | 365,044 | +6.8% | 0.00% | – |
Q4 2021 | $6,726,000 | -40.9% | 341,940 | -3.6% | 0.00% | -100.0% |
Q3 2021 | $11,388,000 | -1.1% | 354,764 | +4.2% | 0.00% | 0.0% |
Q2 2021 | $11,519,000 | +41.2% | 340,303 | +56.7% | 0.00% | – |
Q1 2021 | $8,158,000 | +17.5% | 217,198 | +3.9% | 0.00% | – |
Q4 2020 | $6,945,000 | -11.6% | 209,050 | -2.5% | 0.00% | -100.0% |
Q3 2020 | $7,859,000 | +12.2% | 214,307 | +0.7% | 0.00% | 0.0% |
Q2 2020 | $7,003,000 | +44.8% | 212,807 | +13.6% | 0.00% | – |
Q1 2020 | $4,836,000 | +24.0% | 187,308 | +49.6% | 0.00% | – |
Q4 2019 | $3,900,000 | – | 125,243 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |